Roughly 39% of GLP-1 users reported nail detachment — onycholysis — compared with 9% of matched nonusers, a more than fourfold gap, according to an international survey presented Oct. 1 at the EADV Congress 2026 in Vienna.

The cross-sectional study, led by Dr. Charles Taïeb, compared 575 users of GLP-1 receptor agonists (semaglutide, tirzepatide) with 1,329 controls who had type 2 diabetes, obesity, or both but had never taken the drug class. Participants came from France, the United States, Brazil, and Mexico. All lived with type 2 diabetes, obesity, or both.

What did the survey measure?

Self-reported nail and scalp symptoms, without dermatologic examination:

• Any nail disorder: 66% of users vs. 53% of controls
• Nail discoloration: 46% vs. 17%
• Unusual hair loss: 50% vs. 34% (companion scalp study)
• Loss of hair volume or density: 42% vs. 19%
• Hair loss beginning after treatment start: 26% vs. 12%
• Scalp redness: roughly three times more common among users

"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," Taïeb said in the EADV release. He also cautioned that "not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself."

Is this telogen effluvium or something else?

Rapid weight loss is the standard explanation for GLP-1–associated shedding. The American Academy of Dermatology lists losing 20 pounds or more as a trigger for telogen effluvium, a temporary shedding that typically appears months after the stressor and resolves within six to nine months.

Reduced appetite may also cut intake of protein, iron, and zinc — nutrients hair and nails depend on.

But the researchers said these factors fell short. After adjusting for skin conditions and nutritional deficiencies, nail detachment and discoloration remained two to three times more frequent among users — a difference the EADV release said "did not appear to be explained by weight loss alone."

"This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component," said Dr. Bruno Halioua, author of the companion hair study. He framed the inflammation idea as a hypothesis for further testing, not a finding.

What are the study's limits?

Several, and they matter for interpretation:

• Both studies were self-reported cross-sectional surveys; no clinician examined nails or scalps.
• The design shows association, not causation.
• The data, presented at a medical congress, has not completed formal peer review.
• About half of GLP-1 users reported nail problems before starting treatment.
• Diabetes and obesity independently raise rates of fungal infection, circulatory problems, and thyroid disease, all of which affect nails.
• The work received institutional support from DUCRAY Laboratories, part of the Pierre Fabre Group, which sells hair-care products.

The findings extend a signal that predates this survey. A separate BMJ study using medical records — a stronger design than patient questionnaires — previously linked GLP-1 drugs to hair loss and prompted an FDA safety signal.

Should patients stop treatment?

The authors were unambiguous: no. "These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one's own initiative," Halioua said.

Taïeb told Gizmodo: "For people taking or considering GLP-1 receptor agonists, the main takeaway is: do not panic, and do not stop an effective treatment on your own because of your hair or nails." He advised raising symptoms with a physician.

Clinically, patients noticing lifting, discolored, or brittle nails — or new hair thinning after treatment start — should record onset dates, photograph the changes, and present them to a prescriber or dermatologist. Workup can include fungal testing, thyroid evaluation, iron studies, and a review of protein intake. Nails that become painful, red, swollen, or drain pus warrant prompt evaluation for infection.

The authors call for prospective studies following patients from treatment initiation with standardized dermatological exams — the design that could establish whether nail and scalp changes truly begin after GLP-1 exposure, and how often.